A bispecific antibody inhibits FGFR3 dimerization and is highly effective in FGFR3-driven tumor models

被引：0
|
作者：
Yang, Yan
Avvaru, Naga Suhasini
Jiang, Zaoli
Liu, Nina
Rosconi, Michael
Zhang, Bojie
Li, Yinyin
Ullman, Erica
Lin, John Chia-Yang
Shen, Yang
Daly, Christopher
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2023年 / 22卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-23-B129
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B129
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A first-in-human phase 1 study of LOXO-435, a potent, highly isoform-selective FGFR3 inhibitor in advanced solid tumors with FGFR3 alterations (trial in progress)
    Iyer, Gopa
    Siefker-Radtke, Arlene
    Milowsky, Matthew
    Shore, Neal
    Gao, Xin
    Reimers, Melissa A.
    Hahn, Noah
    Cosman, Rasha
    Matsubara, Nobuaki
    Necchi, Andrea
    Robbrecht, Debbie
    Vinceneux, Armelle
    Grande, Enrique
    Lee, Jae-Lyun
    Zhang, Tian
    Guren, Tormod
    Lauer, Ulrich M.
    Sarfaty, Michal
    Eigl, Bernhard
    Hussain, Syed
    Zhao, Xiang
    Balar, Arjun V.
    Francese, Kaitlyn
    Widau, Ryan
    Garmezy, Benjamin
    CANCER RESEARCH, 2023, 83 (08)
  • [42] Identification of FGFR3 mutations in urine sediment DNA complements cytology in bladder tumor detection
    Mourtzinos, AP
    Rieger-Christ, KM
    Cain, J
    Silverman, M
    Libertino, JA
    Summerhayes, IC
    JOURNAL OF UROLOGY, 2003, 169 (04): : 132 - 132
  • [43] The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer
    Kazumasa Komura
    Kensuke Hirosuna
    Satoshi Tokushige
    Takuya Tsujino
    Kazuki Nishimura
    Mitsuaki Ishida
    Takuo Hayashi
    Ayako Ura
    Takaya Ohno
    Shogo Yamazaki
    Keita Nakamori
    Shoko Kinoshita
    Ryoichi Maenosono
    Masahiko Ajiro
    Yuki Yoshikawa
    Tomoaki Takai
    Takeshi Tsutsumi
    Kohei Taniguchi
    Tomohito Tanaka
    Kiyoshi Takahara
    Tsuyoshi Konuma
    Teruo Inamoto
    Yoshinobu Hirose
    Fumihito Ono
    Yuichi Shiraishi
    Akihide Yoshimi
    Haruhito Azuma
    Molecular Cancer, 22
  • [44] The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer
    Komura, Kazumasa
    Hirosuna, Kensuke
    Tokushige, Satoshi
    Tsujino, Takuya
    Nishimura, Kazuki
    Ishida, Mitsuaki
    Hayashi, Takuo
    Ura, Ayako
    Ohno, Takaya
    Yamazaki, Shogo
    Nakamori, Keita
    Kinoshita, Shoko
    Maenosono, Ryoichi
    Ajiro, Masahiko
    Yoshikawa, Yuki
    Takai, Tomoaki
    Tsutsumi, Takeshi
    Taniguchi, Kohei
    Tanaka, Tomohito
    Takahara, Kiyoshi
    Konuma, Tsuyoshi
    Inamoto, Teruo
    Hirose, Yoshinobu
    Ono, Fumihito
    Shiraishi, Yuichi
    Yoshimi, Akihide
    Azuma, Haruhito
    MOLECULAR CANCER, 2023, 22 (01)
  • [45] FGFR3 Stimulates Stearoyl CoA Desaturase 1 Activity to Promote Bladder Tumor Growth
    Du, Xiangnan
    Wang, Qian-Rena
    Chan, Emily
    Merchant, Mark
    Liu, Jinfeng
    French, Dorothy
    Ashkenazi, Avi
    Qing, Jing
    CANCER RESEARCH, 2012, 72 (22) : 5843 - 5855
  • [46] Alternative format bispecific antibodies targeting multiple oncogenic FGFR3 mutations in bladder cancer through different mechanisms
    Yang, Yan
    Wibowo, Arif
    Avvaru, Suhasini
    Jiang, Zaoli
    Luz, Antonio
    Rafique, Ashique
    Sarangapani, Prasad
    McKay, Ryan
    Amatulli, Michael
    Vootlakrishna, Meghana
    Edwards, Rachel
    Potocky, Terra
    Hermann, Aynur
    Daly, Christopher
    Thurston, Gavin
    Lin, John Chia-Yang
    Shen, Yang
    CANCER RESEARCH, 2020, 80 (16)
  • [47] Preclinical characterization of LOX-24350, a highly potent and isoform-selective FGFR3 inhibitor
    Ballard, Joshua A.
    Kercher, Timothy
    Abraham, David
    Brecht, Ryan
    Brooks, Nathan A.
    Buckles, Thomas
    Bume, Desta
    Busha, David
    Cedervall, Ernst Peder
    Condroski, Kevin
    Ebata, Kevin
    Gharbi, Severine Isabelle
    Hazlitt, Robert
    Morales, Tony
    Patel, Nisha
    Podoll, Jessica
    Urkalan, Kaveri
    Villalain, Sandra Gomez
    Walls, Shane
    Watson, Faith
    Yang, Peiyi
    Brandhuber, Barbara J.
    Andrews, Steven W.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [48] FGFR3 Driven Metastatic Urothelial Carcinoma of the Urinary Bladder (mUCB): A Comprehensive Genomic Profiling Study
    Ross, Jeffrey S.
    Gay, Laurie M.
    Ferry, Elizabeth Kate
    Jacob, Joseph
    Shapiro, Oleg
    Hoffman-Censits, Jean H.
    Millis, Sherri Z.
    Elvin, Julia Andrea
    Chung, Jon
    Vergilio, Jo-Anne
    Suh, James
    Ramkissoon, Shakti H.
    Severson, Eric Allan
    Daniel, Sugganth
    Killian, Jonathan Keith
    Ali, Siraj Mahamed
    Schrock, Alexa Betzig
    Miller, Vincent A.
    Bratslavsky, Gennady
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [49] A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in advanced solid tumors with FGFR3 alterations: Initial results from FORAGER-1.
    Iyer, Gopa
    Ebi, Hiromichi
    Cook, Natalie
    Gao, Xin
    Kitano, Shigehisa
    Matsubara, Nobuaki
    Reimers, Melissa A.
    Siefker-Radtke, Arlene O.
    Kim, Miso
    Galsky, Matthew D.
    Robbrecht, Debbie G. J.
    Guo, Jun
    Eigl, Bernhard J.
    Schaverien, Clare
    Butts, Brent
    Yuen, Eunice
    Szymczak, Sylwia
    Zhao, Xiang
    Widau, Ryan C.
    Drakaki, Alexandra
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [50] A highly selective FGFR3 inhibitor alleviates achondroplasia symptoms and restores chondrocyte growth in mice model
    Han, Tian
    Fu, Donglin
    Xia, Yuanfeng
    Hu, Zhilong
    Yang, Fanglong
    HORMONE RESEARCH IN PAEDIATRICS, 2024, 97 : 35 - 36
12345